TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Liminatus Pharma ( (LIMN) ) just unveiled an announcement.
On November 19, 2025, Liminatus Pharma, Inc. received notifications from Nasdaq indicating non-compliance with certain listing rules due to insufficient market value of listed securities and publicly held shares. The company has been given until May 18, 2026, to regain compliance, failing which it may face delisting or consider transferring to the Nasdaq Capital Market. The company is actively working to meet the requirements, but there is no assurance of success within the given timeframe.
More about Liminatus Pharma
Liminatus Pharma, Inc. operates in the pharmaceutical industry, focusing on the development and commercialization of pharmaceutical products.
Average Trading Volume: 739,764
Technical Sentiment Signal: Sell
Current Market Cap: $22.81M
Learn more about LIMN stock on TipRanks’ Stock Analysis page.